Carbapenems against Mycobacterium tuberculosis: A review of the evidence

Research output: Contribution to journalReview article

Abstract

Carbapenems, a more recent β-lactam class, represent a unique anti-tuberculosis option, as emerging evidence demonstrates that they target the Mycobacterium tuberculosis cell wall and β-lactamase. This provides a potentially new agent against M. tuberculosis, in particular for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), where options are limited. In this review, we examine the current evidence on the activity of carbapenems against M. tuberculosis. The predominance of work is in vitro, and suggests that carbapenems kill M. tuberculosis at least in the active phase, with possible greater potency with the addition of a β-lactamase inhibitor. The few in vivo and clinical studies suggest that there are benefits and that they are generally tolerated, although the variability in duration, dosing, and background regimen and lack of pharmacokinetic analyses limit interpretation of efficacy. We outline further areas of research to better understand the role of carbapenems to add a needed new agent to the treatment of MDR- and XDRTB.

Original languageEnglish (US)
Pages (from-to)1436-1447
Number of pages12
JournalInternational Journal of Tuberculosis and Lung Disease
Volume20
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

    Fingerprint

Keywords

  • Anti-tuberculosis
  • Antibiotics
  • Extensively drug-resistant tuberculosis
  • Group D
  • Multidrug-resistant tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this